Who makes Metformin, dipyridamole?

Metformin, dipyridamole is developed by Radboud University Medical Center.

What development phase is Metformin, dipyridamole in?

Metformin, dipyridamole is FDA-approved (marketed).

Last reviewed 2026-05-15 · How we verify

Metformin, dipyridamole

Radboud University Medical Center · FDA-approved active Small molecule Quality 2/100

Metformin, dipyridamole is a marketed drug developed by Radboud University Medical Center, with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and long-term use, supported by a strong patent protection until 2028. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Metformin, dipyridamole
Sponsor	Radboud University Medical Center
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Metformin-Dipyridamole Interaction Trial (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Metformin, dipyridamole CI brief — competitive landscape report
Metformin, dipyridamole updates RSS · CI watch RSS
Radboud University Medical Center portfolio CI